Jade Biosciences, Inc.(JBIO)Earnings, Financials & Key Ratios

JBIO•NASDAQ

Price updated Jun 11, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryImmunology and Inflammation Therapies

AboutJade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.Show more

Revenue$0
EBITDA-$114M-52.8%
Net Income-$127M-83.0%
EPS (Diluted)-4.06+95.2%
ROE-62.31%+16.8%
ROIC-59.16%+31.4%
Debt/Equity0.00-60.1%

JBIO Key Insights

Jade Biosciences, Inc. (JBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Profits declining 67.7% over 5 years
✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when JBIO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

JBIO Price & Volume

Jade Biosciences, Inc. (JBIO) stock price & volume — 10-year historical chart

Loading chart...

JBIO Growth Metrics

Jade Biosciences, Inc. (JBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-86.04%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM95.61%

Return on Capital

10 Years-94.67%

5 Years-53.15%

3 Years-68.04%

Last Year-55.42%

JBIO Recent Earnings

Jade Biosciences, Inc. (JBIO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 3/6 qtrs (50%)

Q2 2026Latest

May 7, 2026

EPS

$0.57

Est $0.52

-9.6%

Revenue

—

Q2 2026

Mar 6, 2026

EPS

$0.11

Est $0.45

+75.6%

Revenue

—

Q4 2025

Nov 13, 2025

EPS

$0.48

Est $0.57

+15.8%

Revenue

—

Q3 2025

Aug 13, 2025

EPS

$0.86

Est $0.43

-100.0%

Revenue

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 7, 2026	$0.57vs $0.52-9.6%	—
Q2 2026	Mar 6, 2026	$0.11vs $0.45+75.6%	—
Q4 2025	Nov 13, 2025	$0.48vs $0.57+15.8%	—
Q3 2025	Aug 13, 2025	$0.86vs $0.43-100.0%	—

Based on last 6 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
KRYSKrystal Biotech, Inc.Direct Competitor	9.48B	321.55	47.01	33.94%	53.92%	19.25%	0.01
RCUSArcus Biosciences, Inc.Direct Competitor	2.35B	23.30	-7.08	-4.26%	-156.36%	-68.97%	0.16
IMVTImmunovant, Inc.Direct Competitor	6.75B	32.88	-11.87			-68.16%	0.00
ARQTArcutis Biotherapeutics, Inc.Direct Competitor	3.08B	24.59	-189.15	91.34%	-0.57%	-1.41%	0.03
DAWNDay One Biopharmaceuticals, Inc.Direct Competitor	2.22B	21.53	-20.70	20.6%	-67.85%	-23.43%	0.01
REGNRegeneron Pharmaceuticals, Inc.Product Competitor	63.53B	611.48	14.74	0.99%	29.65%	14.32%	0.09
ABBVAbbVie Inc.Product Competitor	397.56B	224.77	94.84	8.57%	6.91%	62.15%
SNDXSyndax Pharmaceuticals, Inc.Product Competitor	1.58B	17.91	-5.44	6.28%	-112.01%	-256.66%	5.36

Compare JBIO vs Peers

Jade Biosciences, Inc. (JBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs KRYS

Most directly comparable listed peer for JBIO.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare JBIO against a more recognizable public peer.

Peer Set

Compare Top 5

vs KRYS, RCUS, IMVT, ARQT

JBIO Income Statement

Jade Biosciences, Inc. (JBIO) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Metric	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold	1K	15K	68K	96K	282K	0	9K
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit	-1K▲ 0%	-15K▼ 1400.0%	-68K▼ 353.3%	-96K▼ 41.2%	-282K▼ 193.8%	0▲ 100.0%	-9K▲ 0%
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1400%	-353.33%	-41.18%	-193.75%	100%	-
Operating Expenses	8.89M	23.01M	53.17M	81.31M	74.31M	113.54M	133.59M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	948K	8.02M	14.55M	17.09M	21.13M	20.42M	24.44M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	7.94M	14.99M	38.62M	64.22M	53.19M	93.12M	109.15M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income	-8.89M▲ 0%	-23.02M▼ 159.0%	-53.24M▼ 131.2%	-81.41M▼ 52.9%	-74.6M▲ 8.4%	-113.54M▼ 52.2%	-133.6M▲ 0%
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-158.99%	-131.24%	-52.92%	8.37%	-52.21%	-
EBITDA	-8.89M	-23.01M	-53.17M	-81.31M	-74.31M	-113.52M	-133.57M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-158.85%	-131.1%	-52.93%	8.61%	-52.75%	-81.98%
D&A (Non-Cash Add-back)	1K	15K	68K	96K	282K	26K	30K
EBIT	-9.54M	-22.96M	-51.49M	-75.47M	-69.57M	-113.54M	-133.6M
Net Interest Income	-75K	65K	1.83M	5.95M	5.04M	7.78M	10.27M
Interest Income	0	65K	1.83M	5.95M	5.04M	7.78M	10.27M
Interest Expense	75K	0	0	0	0	0	0
Other Income/Expense	-722K	62K	1.75M	5.94M	5.02M	-13.81M	4.07M
Pretax Income	-9.61M▲ 0%	-22.96M▼ 138.9%	-51.49M▼ 124.2%	-75.47M▼ 46.6%	-69.57M▲ 7.8%	-127.35M▼ 83.0%	-129.53M▲ 0%
Pretax Margin %	-	-	-	-	-	-	-
Income Tax	0	3K	25K	56K	55K	58K	74K
Effective Tax Rate %	0%	-0.01%	-0.05%	-0.07%	-0.08%	-0.05%	-0.06%
Net Income	-9.61M▲ 0%	-22.96M▼ 138.9%	-51.51M▼ 124.3%	-75.52M▼ 46.6%	-69.63M▲ 7.8%	-127.41M▼ 83.0%	-129.61M▲ 0%
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-138.92%	-124.32%	-46.61%	7.8%	-82.99%	-86.04%
Net Income (Continuing)	-9.61M	-22.96M	-51.51M	-75.52M	-69.63M	-127.41M	-129.61M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)	-14.00▲ 0%	-32.96▼ 135.4%	-73.67▼ 123.5%	-100.38▼ 36.3%	-85.26▲ 15.1%	-4.06▲ 95.2%	-2.24▲ 0%
EPS Growth %	-	-135.41%	-123.54%	-36.26%	15.06%	95.24%	95.61%
EPS (Basic)	-14.00	-32.96	-73.67	-100.38	-85.26	-4.06	-
Diluted Shares Outstanding	697.44K	697.44K	699.2K	752.33K	816.63K	31.36M	57.78M
Basic Shares Outstanding	697.44K	697.44K	699.2K	752.33K	816.63K	31.36M	57.78M
Dividend Payout Ratio	-	-	-	-	-	-	-

JBIO Balance Sheet

Jade Biosciences, Inc. (JBIO) balance sheet — assets, liabilities & shareholders' equity

Metric	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	4.68M	174.33M	131.5M	124.23M	80.12M	336.16M	318.52M
Cash & Short-Term Investments	4.57M	167.38M	129.22M	122.44M	78.62M	336.16M	311.3M
Cash Only	4.57M	54.2M	22.4M	23.49M	33.75M	88.44M	55.09M
Short-Term Investments	0	113.18M	106.82M	98.95M	44.87M	247.72M	256.21M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	103K	240K	295K	250K	845K	0	7.22M
Total Non-Current Assets	39K	1.03M	3.8M	3.19M	215K	13.62M	916K
Property, Plant & Equipment	39K	728K	1.25M	902K	215K	0	847K
Fixed Asset Turnover	-	-	-	-	-	-	0.00x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	302K	2.56M	2.28M	0	13.62M	69K
Total Assets	4.71M▲ 0%	175.36M▲ 3619.3%	135.3M▼ 22.8%	127.42M▼ 5.8%	80.33M▼ 37.0%	349.78M▲ 335.4%	319.43M▲ 0%
Asset Turnover	-	-	-	-	-	-	0.00x
Asset Growth %	-	3619.26%	-22.85%	-5.83%	-36.95%	335.42%	558.51%
Total Current Liabilities	1.77M	2.55M	7.78M	17.64M	3.83M	16.54M	22.29M
Accounts Payable	618K	1.21M	2.58M	2.4M	224K	2.15M	3.98M
Days Payables Outstanding	225.57K	29.39K	13.82K	9.11K	289.93	-	152.75K
Short-Term Debt	0	192K	385K	420K	417K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	964K	360K	3.13M	10.45M	319K	14.39M	15.57M
Current Ratio	2.64x	68.37x	16.90x	7.04x	20.93x	20.33x	14.29x
Quick Ratio	2.64x	68.37x	16.90x	7.04x	20.93x	20.33x	14.29x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities	0	395K	776K	325K	70K	724K	679K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	382K	705K	255K	0	724K	2.94M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	13K	71K	70K	70K	0	0
Total Liabilities	1.77M	2.94M	8.56M	17.96M	3.9M	17.26M	22.97M
Total Debt	0	574K	1.09M	675K	417K	724K	679K
Net Debt	-4.57M	-53.62M	-21.31M	-22.82M	-33.33M	-87.71M	-54.41M
Debt / Equity	-	0.00x	0.01x	0.01x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-0.01x
Net Debt / EBITDA	-	-	-	-	-	-	0.41x
Interest Coverage	-127.15x	-	-	-	-	-	-
Total Equity	2.94M▲ 0%	172.42M▲ 5762.6%	126.74M▼ 26.5%	109.46M▼ 13.6%	76.43M▼ 30.2%	332.52M▲ 335.0%	296.46M▲ 0%
Equity Growth %	-	5762.56%	-26.49%	-13.64%	-30.17%	335.04%	571.37%
Book Value per Share	4.22	247.22	181.27	145.49	93.60	10.60	5.13
Total Shareholders' Equity	2.94M	172.42M	126.74M	109.46M	76.43M	332.52M	296.46M
Common Stock	0	2K	2K	3K	3K	5K	5K
Retained Earnings	-13.41M	-36.39M	-87.9M	-163.42M	-233.05M	-174.39M	-214.76M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	-59K	-466K	237K	105K	129K	-342K
Minority Interest	0	0	0	0	0	0	0

JBIO Cash Flow Statement

Jade Biosciences, Inc. (JBIO) cash flow — operating, investing & free cash flow history

Metric	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	-7.86M	-27.4M	-39.12M	-56.78M	-71.2M	-94.69M	-116.39M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-248.63%	-42.79%	-45.13%	-25.39%	-33%	-442.71%
Net Income	-9.61M	-22.96M	-51.51M	-75.52M	-69.63M	-127.41M	-129.61M
Depreciation & Amortization	1K	15K	68K	96K	282K	0	22K
Stock-Based Compensation	0	0	0	0	0	0	4.29M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	777K	2.06M	4.57M	8.85M	9.32M	40.92M	6.93M
Working Capital Changes	974K	-6.51M	7.75M	9.8M	-11.17M	-8.2M	1.97M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	37K	609K	1.37M	-164K	-2.17M	361K	2.84M
Cash from Investing	0	-113.43M	6.93M	11.88M	56.03M	-247.01M	-268.33M
Capital Expenditures	0	-181K	-195K	-142K	0	-196K	-196K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	-246.81M	-98.22M
Cash from Financing	8.92M	190.46M	396K	46M	25.43M	360.77M	359.97M
Debt Issued (Net)	2.5M	0	0	0	0	0	0
Equity Issued (Net)	6.42M	190.46M	396K	46M	25.43M	360.61M	360.66M
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0
Other Financing	0	0	0	0	0	156K	-684K
Net Change in Cash	1.06M▲ 0%	49.62M▲ 4585.9%	-31.8M▼ 164.1%	1.09M▲ 103.4%	10.26M▲ 837.8%	-33.75M▼ 429.0%	-77.57M▲ 0%
Free Cash Flow	-7.86M▲ 0%	-27.58M▼ 250.9%	-39.32M▼ 42.6%	-56.92M▼ 44.8%	-71.2M▼ 25.1%	-94.89M▼ 33.3%	-116.58M▲ 0%
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-250.94%	-42.56%	-44.77%	-25.08%	-33.27%	-553.17%
FCF per Share	-11.27	-39.54	-56.23	-75.66	-87.18	-3.03	-2.02
FCF Conversion (FCF/Net Income)	0.82x	1.19x	0.76x	0.75x	1.02x	0.74x	0.90x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

JBIO Key Ratios

Jade Biosciences, Inc. (JBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-26.19%	-34.44%	-63.95%	-74.91%	-62.31%	-51.34%
Return on Invested Capital (ROIC)	-29.47%	-35.61%	-63.58%	-86.24%	-59.16%	-67%
Debt / Equity	0.00x	0.01x	0.01x	0.01x	0.00x	0.00x
FCF Conversion	1.19x	0.76x	0.75x	1.02x	0.74x	0.90x

JBIO Frequently Asked Questions

Jade Biosciences, Inc. (JBIO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Jade Biosciences, Inc. (JBIO) grew revenue by 0.0% over the past year. Growth has been modest.

Jade Biosciences, Inc. (JBIO) reported a net loss of $129.6M for fiscal year 2025.

Dividend & Returns

Jade Biosciences, Inc. (JBIO) has a return on equity (ROE) of -62.3%. Negative ROE indicates the company is unprofitable.

Jade Biosciences, Inc. (JBIO) had negative free cash flow of $116.6M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in JBIO back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →

How much would $100/month in JBIO be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →

Jade Biosciences, Inc.(JBIO)Earnings, Financials & Key Ratios

JBIO•NASDAQ

Price updated Jun 11, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryImmunology and Inflammation Therapies

Revenue$0
EBITDA-$114M-52.8%
Net Income-$127M-83.0%
EPS (Diluted)-4.06+95.2%
ROE-62.31%+16.8%
ROIC-59.16%+31.4%
Debt/Equity0.00-60.1%